CANDEL THERAPEUTICS INC (CADL)
Health Care · Viral immunotherapy / immuno-oncology · NASDAQ
Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic cell death within solid tumors.
What CANDEL THERAPEUTICS INC does
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to elicit individualized, systemic anti-tumor immune responses to fight cancer. The company has established two clinical platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, administered locally into tumors to induce immunogenic cell death and trigger both local and systemic (abscopal) immune responses against injected and distant uninjected tumors. The company's lead candidate, aglatimagene besadenovec, is an adenovirus product administered with the prodrug valacyclovir and has demonstrated clinical activity across multiple solid tumor indications, including a recently announced positive Phase 3 trial in localized prostate cancer.
Themes: ["Viral immunotherapy / oncolytic viruses","Cancer immunotherapy","Immuno-oncology","Personalized / individualized cancer treatment","Cold-to-hot tumor transformation"]
Fundamentals
- Price$9.89 as of 2026-07-09 close
- Market cap$725M as of 2026-07-10
- 1-year return+88.5% as of 2026-07-09 close
- Net margin-15156.5% as of 2026-07-10
- ROE-60.4% as of 2026-07-10
- Debt / equity0.34 as of 2026-07-10
- Revenue CAGR (3y)+0.0% SEC XBRL
- Beta-0.46 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: all product candidates are in clinical stages; aglatimagene's Phase 3 prostate cancer trial showed statistically significant but modest DFS improvement (HR 0.70), which may not translate to commercial success or regulatory approval","Regulatory and manufacturing complexity: as a viral vector therapy, the company faces stringent FDA approval pathways and significant manufacturing/GMP challenges for off-the-shelf viral immunotherapies","Significant operating losses and cash burn: the company posted a net loss of $8.9M in Q1 2026 with R&D and G&A expenses of $16.3M; unprofitable with limited revenue, facing runway pressures despite recent capital raises"]
Competitors & peers
- Replimune (REPL) — oncolytic virus immunotherapy developer
- Western Oncolytics — oncolytic adenovirus platform
- Targovax — viral vector immunotherapy
- Jennerex — oncolytic viral platform
- Conventional immuno-oncology competitors (checkpoint inhibitors, CAR-T): Merck (MRK), Bristol Myers Squibb (BMY), Regeneron (REGN)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.